Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
angiogenesis
combination
immune checkpoint inhibitors
immunotherapy
renal cell carcinoma
tyrosine kinase inhibitors
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
09
2019
accepted:
15
01
2020
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
28
3
2020
Statut:
epublish
Résumé
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have improved outcomes of patients and modified the natural history of mRCC. Clinical investigations have focused on evaluating combination regimens containing ICIs and VEGFR-directed TKIs. Namely, the combinations of axitinib plus pembrolizumab (KEYNOTE-426) and axitinib plus avelumab (JAVELIN RENAL 101) have shown improved outcomes compared with sunitinib in treatment-naïve patients with mRCC. In this review, we discuss the clinical data of single-agent TKIs and ICIs in mRCC and the rationale for the combination ICIs and TKIs based on preclinical and clinical evidence. We also explore the current challenges for regimen selection and development of predictive biomarkers.
Identifiants
pubmed: 32215057
doi: 10.1177/1758835920907504
pii: 10.1177_1758835920907504
pmc: PMC7081462
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835920907504Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: Elie Rassy and Ronan Flippot: none Laurence Albiges: Consulting/advisory role: Novartis (Institution), Amgen (Institution), Bristol-Myers Squibb (Institution), Ipsen (Institution), Roche (Institution), Pfizer (Institution), Astellas Pharma (Institution), Merck (Institution), MSD (Institution), AstraZeneca (Institution), Exelixis (Institution), Corvus Pharmaceuticals (Institution), Peloton therapeutics (Institution). Research Funding: Bristol-Myers Squibb (Institution).
Références
Lancet Oncol. 2018 Apr;19(4):451-460
pubmed: 29530667
J Immunol. 2008 Jul 1;181(1):346-53
pubmed: 18566400
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Clin Genitourin Cancer. 2021 Oct;19(5):434-446
pubmed: 34006498
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Immunotherapy. 2018 Sep;10(12):1047-1052
pubmed: 30185138
Eur Urol. 2019 Dec;76(6):861-867
pubmed: 31445844
Br J Cancer. 2009 Apr 7;100(7):1111-9
pubmed: 19277038
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2007 Dec 22;370(9605):2103-11
pubmed: 18156031
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Blood. 2007 Jul 15;110(2):624-31
pubmed: 17376891
Clin Cancer Res. 2008 Aug 1;14(15):4726-34
pubmed: 18676741
Eur J Cancer. 2018 May;94:115-125
pubmed: 29550566
Blood. 2003 Jun 15;101(12):4878-86
pubmed: 12586633
Clin Cancer Res. 2012 Mar 1;18(5):1207-13
pubmed: 22205687
Br J Cancer. 2012 Nov 20;107(11):1869-75
pubmed: 23169339
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
J Neuroinflammation. 2011 Nov 08;8:155
pubmed: 22067141
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Eur Urol Oncol. 2019 Nov;2(6):708-715
pubmed: 31588018
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Clin Exp Immunol. 2013 Jun;172(3):500-6
pubmed: 23600839
N Engl J Med. 2018 Apr 5;378(14):1344-1345
pubmed: 29562143
Cancer Immunol Immunother. 2008 Aug;57(8):1115-24
pubmed: 18193223
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
FASEB J. 2015 Jan;29(1):227-38
pubmed: 25361735
Nat Rev Immunol. 2011 Sep 23;11(10):702-11
pubmed: 21941296
J Immunother. 2010 Nov-Dec;33(9):991-8
pubmed: 20948437
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
Trends Mol Med. 2004 Sep;10(9):466-72
pubmed: 15350900
Ann Oncol. 2016 Sep;27(suppl 5):v58-v68
pubmed: 27664262
Cancer Cell. 2007 Jun;11(6):539-54
pubmed: 17560335
J Clin Oncol. 2008 Nov 20;26(33):5422-8
pubmed: 18936475
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Oncologist. 2011;16 Suppl 2:14-22
pubmed: 21346036
Cancer Res. 2013 May 15;73(10):2943-8
pubmed: 23440426
Cancer Res. 1996 Mar 1;56(5):1111-17
pubmed: 8640769
Future Oncol. 2017 Aug;13(19):1669-1671
pubmed: 28831825
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
Invest New Drugs. 2012 Aug;30(4):1791-801
pubmed: 21573959
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Semin Cancer Biol. 2013 Feb;23(1):38-45
pubmed: 22705280
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
J Immunother Cancer. 2018 Jan 25;6(1):4
pubmed: 29368638
Eur Urol Oncol. 2019 Sep;2(5):505-514
pubmed: 31377308
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381